Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer

• Published in: International journal of molecular sciences Vol. 25; no. 10; p. 5408
• Main Authors: Gretschel, Julius, El Hage, Racha, Wang, Ruirui, Chen, Yifang, Pietzner, Anne, Loew, Andreas, Leineweber, Can G, Wördemann, Jonas, Rohwer, Nadine, Weylandt, Karsten H, Schmöcker, Christoph
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.05.2024
• Subjects: Animals; Anti-inflammatory agents; Arachidonic acid; ASA; aspirin; Cancer; Cancer therapies; Care and treatment; Cell growth; Colorectal cancer; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Colorectal Neoplasms - prevention & control; Enzymes; Fatty acids; Fatty Acids, Omega-6 - metabolism; Fatty Acids, Omega-6 - therapeutic use; Fish oils; Humans; Immunotherapy; Inflammation; Inflammation - metabolism; Lifestyles; Metastasis; Nonsteroidal anti-inflammatory drugs; Nutrition research; omega-3 PUFA; Oxylipins - metabolism; Physiological aspects; Rankings; statin; Tumors; Unsaturated fatty acids; Germany; arachidonic acid; colorectal cancer; statin; prostaglandin E2; aspirin; metformin; omega-3 PUFA; immune checkpoint inhibitors; ASA
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25105408

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, ranking as the third most malignant. The incidence of CRC has been increasing with time, and it is reported that Westernized diet and lifestyle play a significant role in its higher incidence and rapid progression. The intake of high amounts of omega-6 ( - 6) PUFAs and low levels of omega-3 ( - 3) PUFAs has an important role in chronic inflammation and cancer progression, which could be associated with the increase in CRC prevalence. Oxylipins generated from PUFAs are bioactive lipid mediators and have various functions, especially in inflammation and proliferation. Carcinogenesis is often a consequence of chronic inflammation, and evidence has shown the particular involvement of - 6 PUFA arachidonic acid-derived oxylipins in CRC, which is further described in this review. A deeper understanding of the role and metabolism of PUFAs by their modifying enzymes, their pathways, and the corresponding oxylipins may allow us to identify new approaches to employ oxylipin-associated immunomodulation to enhance immunotherapy in cancer. This paper summarizes oxylipins identified in the context of the initiation, development, and metastasis of CRC. We further explore CRC chemo-prevention strategies that involve oxylipins as potential therapeutics.